Captrust Financial Advisors Has $9.94 Million Stock Position in ICON Public Limited (NASDAQ:ICLR)

Captrust Financial Advisors lessened its position in ICON Public Limited (NASDAQ:ICLR) by 2.8% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 34,600 shares of the medical research company’s stock after selling 996 shares during the period. Captrust Financial Advisors’ holdings in ICON Public were worth $9,941,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Icon Wealth Advisors LLC grew its position in ICON Public by 861.1% in the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after purchasing an additional 11,840 shares during the period. First Horizon Advisors Inc. grew its holdings in shares of ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after buying an additional 151 shares during the last quarter. Arkadios Wealth Advisors increased its position in shares of ICON Public by 5.0% during the third quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock worth $371,000 after acquiring an additional 62 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of ICON Public by 23.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after acquiring an additional 96 shares during the last quarter. Finally, Whittier Trust Co. lifted its position in ICON Public by 12.3% in the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock valued at $1,155,000 after acquiring an additional 441 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

ICLR has been the subject of several analyst reports. StockNews.com downgraded ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. TD Cowen lowered their price target on ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Redburn Atlantic started coverage on shares of ICON Public in a report on Monday, October 14th. They set a “neutral” rating and a $311.00 price objective on the stock. Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a report on Wednesday, September 18th. Finally, Barclays dropped their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $292.45.

ICON Public Stock Performance

NASDAQ:ICLR opened at $210.25 on Monday. ICON Public Limited has a 1 year low of $183.38 and a 1 year high of $347.72. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. The business has a fifty day simple moving average of $249.33 and a two-hundred day simple moving average of $294.12. The company has a market capitalization of $17.34 billion, a P/E ratio of 23.44, a P/E/G ratio of 1.56 and a beta of 1.25.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.10 earnings per share. On average, analysts expect that ICON Public Limited will post 13.42 earnings per share for the current year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.